{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.471","value":"1.3032"},{"groupId":"OG001","spread":"57.938","value":"0.9485"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3326595. Time invariance was calculated as the ratio of AUC(0-24) on Day 15 divided by AUC(0-infinity) on Day 1 for GSK3326595.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG000","title":"Part 1: GSK3326595 400 mg"},{"description":"Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG001","title":"Part 1: GSK3326595 300 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Days1and15:Pre-dose(within 1hour prior to dosing),5minute(+/-2minute),30minute(+/-5minute),1hour(+/-5minute),2hour(+/-5minute),3hours(+/-5minute),4hours(+/-10minute),6hours(+/-10minute),8hours(+/-15minute),12hours(+/-2hour),24hours(+/-2hour)post-dose","title":"Part 1: Time Invariance Following Administration of GSK3326595","type":"SECONDARY","unitOfMeasure":"Ratio"}